Low-Dose Rapamycin for Longevity
Current understanding
Low-dose weekly or daily rapamycin (typically 1–6 mg) is one of the most-discussed off-label longevity protocols, promoted by clinicians and biohackers on the basis of mTOR-inhibition lifespan effects in mice [animal-model] and a growing but still small human-trial base [human-observational / early human-rct]. A 2026 pilot single-arm trial (1 mg/day × 4 weeks) reported >15% increases in cerebral blood flow plus metabolic and inflammatory shifts specifically in middle-aged APOE4 carriers, with minimal CBF change in non-carriers [human-observational, pilot, uncontrolled], extending the trend into genotype-stratified cerebrovascular endpoints. Trend momentum runs well ahead of controlled outcome data.
Evidence log
- 2026-09-10 — EXPRESS: Rapamycin increases cerebral blood flow and modulates metabolic, inflammatory, and microbiome profiles in healthy middle-aged APOE4 carriers: a pilot single-arm trial.: cross-connection with precision-geromedicine-protocols: APOE4-stratified rapamycin response is a concrete instantiation of gerotype-tailored precision geromedicine — same drug, divergent effect by genotype. (novelty: 3)